NewAmsterdam Pharma (NAMS) EBIT Margin (2023 - 2025)
Historic EBIT Margin for NewAmsterdam Pharma (NAMS) over the last 3 years, with Q3 2025 value amounting to 15845.69%.
- NewAmsterdam Pharma's EBIT Margin fell 157598000.0% to 15845.69% in Q3 2025 from the same period last year, while for Sep 2025 it was 575.81%, marking a year-over-year decrease of 276900.0%. This contributed to the annual value of 386.91% for FY2024, which is 9116500.0% up from last year.
- Per NewAmsterdam Pharma's latest filing, its EBIT Margin stood at 15845.69% for Q3 2025, which was down 157598000.0% from 186.13% recorded in Q2 2025.
- NewAmsterdam Pharma's 5-year EBIT Margin high stood at 85.89% for Q3 2024, and its period low was 15845.69% during Q3 2025.
- Over the past 3 years, NewAmsterdam Pharma's median EBIT Margin value was 2306.93% (recorded in 2024), while the average stood at 3274.48%.
- Its EBIT Margin has fluctuated over the past 5 years, first skyrocketed by 60219300bps in 2024, then plummeted by -157598000bps in 2025.
- NewAmsterdam Pharma's EBIT Margin (Quarter) stood at 6360.4% in 2023, then soared by 95bps to 338.47% in 2024, then crashed by -4582bps to 15845.69% in 2025.
- Its EBIT Margin was 15845.69% in Q3 2025, compared to 186.13% in Q2 2025 and 2314.47% in Q1 2025.